Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 234726, 11 pages
http://dx.doi.org/10.1155/2012/234726
Review Article

Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art

Department of Surgery, Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, 333 Cedar Street, TMP202, Box 208062, New Haven, CT 06520, USA

Received 26 May 2012; Revised 13 August 2012; Accepted 27 August 2012

Academic Editor: Bruce H. R. Wolffenbuttel

Copyright © 2012 Amir H. Lebastchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. L. Wajchenberg, M. A. Albergaria Pereira, B. B. Medonca et al., “Adrenocortical carcinoma: clinical and laboratory observations,” Cancer, vol. 88, no. 4, pp. 711–736, 2000. View at Google Scholar
  2. M. Fassnacht, C. Wittekind, and B. Allolio, “Current TNM classification systems for adrenocortical carcinoma,” Pathologe, vol. 31, no. 5, pp. 374–378, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu, “Molecular markers and the pathogenesis of adrenocortical cancer,” Oncologist, vol. 13, no. 5, pp. 548–561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Fassnacht and B. Allolio, “Clinical management of adrenocortical carcinoma,” Best Practice and Research, vol. 23, no. 2, pp. 273–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Zini, F. Porpiglia, and M. Fassnacht, “Contemporary management of adrenocortical carcinoma,” European Urology, vol. 60, no. 5, pp. 1055–1065, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. M. Weiss, L. J. Medeiros, and A. L. Vickery, “Pathologic features of prognostic significance in adrenocortical carcinoma,” American Journal of Surgical Pathology, vol. 13, no. 3, pp. 202–206, 1989. View at Google Scholar · View at Scopus
  7. G. W. L. Boland, M. A. Blake, P. F. Hahn, and W. W. Mayo-Smith, “Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization,” Radiology, vol. 249, no. 3, pp. 756–775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. W. F. Young Jr., “Conventional imaging in adrenocortical carcinoma: update and perspectives,” Hormones and Cancer, vol. 2, no. 6, pp. 341–347, 2011. View at Google Scholar
  9. A. H. Hamrahian, A. G. Ioachimescu, E. M. Remer et al., “Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: cleveland clinic experience,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 2, pp. 871–877, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Arlt, M. Biehl, A. E. Taylor et al., “Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 12, pp. 3775–3784, 2011. View at Google Scholar
  11. A. T. Phan, “Adrenal cortical carcinoma-review of current knowledge and treatment practices,” Hematology/Oncology Clinics of North America, vol. 21, no. 3, pp. 489–507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Lughezzani, M. Sun, P. Perrotte et al., “The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation,” European Journal of Cancer, vol. 46, no. 4, pp. 713–719, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Allolio and M. Fassnacht, “Clinical review: adrenocortical carcinoma: clinical update,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2027–2037, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Fassnacht, S. Johanssen, M. Quinkler et al., “Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification,” Cancer, vol. 115, no. 2, pp. 243–250, 2009. View at Google Scholar · View at Scopus
  15. E. Kebebew, E. Reiff, Q. Y. Duh, O. H. Clark, and A. McMillan, “Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress?” World Journal of Surgery, vol. 30, no. 5, pp. 872–878, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Sullivan, M. Boileau, and C. V. Hodges, “Adrenal cortical carcinoma,” Journal of Urology, vol. 120, no. 6, pp. 660–665, 1978. View at Google Scholar · View at Scopus
  17. P. Icard, P. Goudet, C. Charpenay et al., “Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group,” World Journal of Surgery, vol. 25, no. 7, pp. 891–897, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. R. A. DeLellis, Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours, IARC Press, Lyon, France, 2004.
  19. R. J. Gonzalez, S. Shapiro, N. Sarlis et al., “Laparoscopic resection of adrenal cortical carcinoma: a cautionary note,” Surgery, vol. 138, no. 6, pp. 1078–1085, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Crucitti, R. Bellantone, A. Ferrante et al., “The italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients,” Surgery, vol. 119, no. 2, pp. 161–170, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Terzolo, A. Pia, A. Berruti et al., “Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 6, pp. 2234–2238, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Terzolo, A. Angeli, M. Fassnacht et al., “Adjuvant mitotane treatment for adrenocortical carcinoma,” The New England Journal of Medicine, vol. 356, no. 23, pp. 2372–2380, 2007. View at Google Scholar
  23. M. L. Kendrick, R. Lloyd, L. Erickson et al., “Adrenocortical carcinoma: surgical progress or status quo?” Archives of Surgery, vol. 136, no. 5, pp. 543–549, 2001. View at Google Scholar · View at Scopus
  24. J. F. Henry, F. Sebag, M. Iacobone, and E. Mirallie, “Results of laparoscopic adrenalectomy for large and potentially malignant tumors,” World Journal of Surgery, vol. 26, no. 8, pp. 1043–1047, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Porpiglia, C. Fiori, R. Tarabuzzi et al., “Is laparoscopic adrenalectomy feasible for adrenocortical carcinoma or metastasis?” BJU International, vol. 94, no. 7, pp. 1026–1029, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Corcione, L. Miranda, E. Marzano et al., “Laparoscopic adrenalectomy for malignant neoplasm: our experience in 15 cases,” Surgical Endoscopy and Other Interventional Techniques, vol. 19, no. 6, pp. 841–844, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. F. F. Palazzo, F. Sebag, M. Sierra, G. Ippolito, P. Souteyrand, and J. F. Henry, “Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors,” World Journal of Surgery, vol. 30, no. 5, pp. 893–898, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. P. Lombardi, M. Raffaelli, C. De Crea, and R. Bellantone, “Role of laparoscopy in the management of adrenal malignancies,” Journal of Surgical Oncology, vol. 94, no. 2, pp. 128–131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. C. H. Liao, S. C. Chueh, M. K. Lai, P. J. Hsiao, and J. Chen, “Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3080–3083, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Nocca, R. Aggarwal, A. Mathieu et al., “Laparoscopic surgery and corticoadrenalomas,” Surgical Endoscopy and Other Interventional Techniques, vol. 21, no. 8, pp. 1373–1376, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Ramacciato, P. Mercantini, M. L. Torre et al., “Is laparoscopic adrenalectomy safe and effective for adrenal masses larger than 7 cm?” Surgical Endoscopy and Other Interventional Techniques, vol. 22, no. 2, pp. 516–521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Brix, B. Allolio, W. Fenske et al., “Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients,” European Urology, vol. 58, no. 6, p. e53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. B. S. Miller, J. B. Ammori, P. G. Gauger, J. T. Broome, G. D. Hammer, and G. M. Doherty, “Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma,” World Journal of Surgery, vol. 34, no. 6, pp. 1380–1385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. J. E. Lee, D. H. Berger, A. K. El-Naggar et al., “Surgical management, DNA content, and patient survival in adrenal cortical carcinoma,” Surgery, vol. 118, no. 6, pp. 1090–1098, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. R. D. Schulick and M. F. Brennan, “Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma,” Annals of Surgical Oncology, vol. 6, no. 8, pp. 719–726, 1999. View at Google Scholar · View at Scopus
  36. D. E. Schteingart, G. M. Doherty, P. G. Gauger et al., “Management of patients with adrenal cancer: recommendations of an international consensus conference,” Endocrine-Related Cancer, vol. 12, no. 3, pp. 667–680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Chiche, B. Dousset, E. Kieffer, and Y. Chapuis, “Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature,” Surgery, vol. 139, no. 1, pp. 15–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Reibetanz, C. Jurowich, I. Erdogan et al., “Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma,” Annals of Surgery, vol. 255, no. 2, pp. 363–369, 2012. View at Google Scholar
  39. R. Bellantone, A. Ferrante, M. Boscherini et al., “Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma,” Surgery, vol. 122, no. 6, pp. 1212–1218, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Icard, Y. Chapuis, B. Andreassian, A. Bernard, and C. Proye, “Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery,” Surgery, vol. 112, no. 6, pp. 972–980, 1992. View at Google Scholar · View at Scopus
  41. C. D. Smith, C. J. Weber, and J. R. Amerson, “Laparoscopic adrenalectomy: new gold standard,” World Journal of Surgery, vol. 23, no. 4, pp. 389–396, 1999. View at Google Scholar · View at Scopus
  42. I. S. Gill, “The case for laparoscopic adrenalectomy,” Journal of Urology, vol. 166, no. 2, pp. 429–436, 2001. View at Google Scholar · View at Scopus
  43. F. Porpiglia, C. Fiori, F. Daffara et al., “Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer,” European Urology, vol. 57, no. 5, pp. 873–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. C. P. Lombardi, M. Raffaelli, M. Boniardi et al., “Adrenocortical carcinoma: effect of hospital volume on patient outcome,” Langenbeck's Archives of Surgery, vol. 397, no. 2, pp. 201–207, 2012. View at Google Scholar
  45. H. S. Park, S. A. Roman, and J. A. Sosa, “Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty?” Archives of Surgery, vol. 144, no. 11, pp. 1060–1067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. R. D. Schulick and M. F. Brennan, “Adrenocortical carcinoma,” World Journal of Urology, vol. 17, no. 1, pp. 26–34, 1999. View at Google Scholar · View at Scopus
  47. J. P. Luton, S. Cerdas, L. Billaud et al., “Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy,” The New England Journal of Medicine, vol. 322, no. 17, pp. 1195–1201, 1990. View at Google Scholar · View at Scopus
  48. A. M. Hutter Jr. and D. E. Kayhoe, “Adrenal cortical carcinoma. Clinical features of 138 patients,” The American Journal of Medicine, vol. 41, no. 4, pp. 572–580, 1966. View at Google Scholar · View at Scopus
  49. M. B. Lipsett, R. Hertz, and G. T. Ross, “Clinical and pathophysiologic aspects of adrenocortical carcinoma,” The American Journal of Medicine, vol. 35, no. 3, pp. 374–383, 1963. View at Google Scholar · View at Scopus
  50. K. Cohn, L. Gottesman, and M. Brennan, “Adrenocortical carcinoma,” Surgery, vol. 100, no. 6, pp. 1170–1177, 1986. View at Google Scholar · View at Scopus
  51. B. Percarpio and A. H. Knowlton, “Radiation therapy of adrenal corticol carcinoma,” Acta Radiologica, vol. 15, no. 4, pp. 288–292, 1976. View at Google Scholar · View at Scopus
  52. S. E. Rodgers et al., “Adrenocortical carcinoma,” Surgical Oncology Clinics of North America, vol. 15, no. 3, pp. 535–553, 2006. View at Google Scholar
  53. B. Polat, M. Fassnacht, L. Pfreundner et al., “Radiotherapy in adrenocortical carcinoma,” Cancer, vol. 115, no. 13, pp. 2816–2823, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. I. G. C. Hermsen, Y. E. Groenen, M. W. Dercksen, J. Theuws, and H. R. Haak, “Response to radiation therapy in adrenocortical carcinoma,” Journal of Endocrinological Investigation, vol. 33, no. 10, pp. 712–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. A. Milgrom and K. A. Goodman, “The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases,” Journal of Surgical Oncology, vol. 106, no. 5, pp. 647–650, 2012. View at Google Scholar
  56. A. Sabolch, M. Feng, K. Griffith, G. Hammer, G. Doherty, and E. Ben-Josef, “Adjuvant and definitive radiotherapy for adrenocortical carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 80, no. 5, pp. 1477–1484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Fassnacht, S. Hahner, B. Polat et al., “Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4501–4504, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. D. E. Schteingart, “Adjuvant mitotane therapy of adrenal cancer—use and controversy,” The New England Journal of Medicine, vol. 356, no. 23, pp. 2415–2418, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Lafemina and M. F. Brennan, “Adrenocortical carcinoma: past, present, and future,” Journal of Surgical Oncology, vol. 106, no. 5, pp. 586–594, 2012. View at Google Scholar
  60. H. R. Haak, J. Hermans, C. J. H. Van de Velde et al., “Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients,” British Journal of Cancer, vol. 69, no. 5, pp. 947–951, 1994. View at Google Scholar · View at Scopus
  61. H. van Slooten, A. J. Moolenaar, A. P. Van Seters, and D. Smeenk, “The treatment of adenocortical carcinoma with o,p′-DDD: prognostic simplications of serum level monitoring,” European Journal of Cancer and Clinical Oncology, vol. 20, no. 1, pp. 47–53, 1984. View at Google Scholar · View at Scopus
  62. E. Baudin, G. Pellegriti, M. Bonnay et al., “Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p′DDD) levels on the treatment of patients with adrenocortical carcinoma,” Cancer, vol. 92, no. 6, pp. 1385–1392, 2001. View at Google Scholar
  63. A. Faggiano, S. Leboulleux, J. Young, M. Schlumberger, and E. Baudin, “Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results,” Clinical Endocrinology, vol. 64, no. 1, pp. 110–113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Daffara, S. de Francia, G. Reimondo et al., “Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly,” Endocrine-Related Cancer, vol. 15, no. 4, pp. 1043–1053, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Vassilopoulou-Sellin, V. F. Guinee, M. J. Klein et al., “Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer,” Cancer, vol. 71, no. 10, pp. 3119–3123, 1993. View at Google Scholar · View at Scopus
  66. B. Bodie, A. C. Novick, J. E. Pontes et al., “The Cleveland Clinic experience with adrenal cortical carcinoma,” Journal of Urology, vol. 141, no. 2, pp. 257–260, 1989. View at Google Scholar · View at Scopus
  67. A. A. Kasperlik-Zaluska, B. M. Migdalska, S. Zgliczyński, and A. M. Makowska, “Adrenocortical carcinoma. A clinical study and treatment results of 52 patients,” Cancer, vol. 75, no. 10, pp. 2587–2591, 1995. View at Google Scholar
  68. A. Berruti, M. Fassnacht, E. Baudin et al., “Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel,” Journal of Clinical Oncology, vol. 28, no. 23, pp. e401–e402, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Hahner and M. Fassnacht, “Mitotane for adrenocortical carcinoma treatment,” Current Opinion in Investigational Drugs, vol. 6, no. 4, pp. 386–394, 2005. View at Google Scholar · View at Scopus
  70. B. Wängberg, A. Khorram-Manesh, S. Jansson et al., “The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane,” Endocrine-Related Cancer, vol. 17, no. 1, pp. 265–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. I. Ilias, M. Alevizaki, G. Philippou, E. Anastasiou, and A. Souvatzoglou, “Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane,” Journal of Endocrinological Investigation, vol. 24, no. 7, pp. 532–535, 2001. View at Google Scholar · View at Scopus
  72. R. J. Gonzalez, E. P. Tamm, C. Ng et al., “Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma,” Surgery, vol. 142, no. 6, pp. 867–875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. T. S. Khan, H. Imam, C. Juhlin et al., “Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use,” Annals of Oncology, vol. 11, no. 10, pp. 1281–1287, 2000. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Berruti, M. Terzolo, P. Sperone et al., “Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial,” Endocrine-Related Cancer, vol. 12, no. 3, pp. 657–666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Fassnacht, M. Terzolo, B. Allolio et al., “Combination chemotherapy in advanced adrenocortical carcinoma,” The New England Journal of Medicine, vol. 366, no. 23, pp. 2189–2197, 2012. View at Google Scholar
  76. T. J. Giordano, D. G. Thomas, R. Kuick et al., “Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis,” American Journal of Pathology, vol. 162, no. 2, pp. 521–531, 2003. View at Google Scholar · View at Scopus
  77. F. de Fraipont, M. El Atifi, N. Cherradi et al., “Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1819–1829, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. P. S. H. Soon, A. J. Gill, D. E. Benn et al., “Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas,” Endocrine-Related Cancer, vol. 16, no. 2, pp. 573–583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Velázquez-Fernández, C. Laurell, J. Geli et al., “Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy,” Surgery, vol. 138, no. 6, pp. 1087–1094, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. E. P. Slater, S. M. Diehl, P. Langer et al., “Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors,” European Journal of Endocrinology, vol. 154, no. 4, pp. 587–598, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. P. M. Szabó, V. Tamási, V. Molnár et al., “Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed,” Oncogene, vol. 29, no. 21, pp. 3163–3172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Gicquel, X. Bertagna, V. Gaston et al., “Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors,” Cancer Research, vol. 61, no. 18, pp. 6762–6767, 2001. View at Google Scholar · View at Scopus
  83. C. Gicquel, M. L. Raffin-Sanson, V. Gaston et al., “Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 8, pp. 2559–2565, 1997. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Arora and E. M. Scholar, “Role of tyrosine kinase inhibitors in cancer therapy,” Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 3, pp. 971–979, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Quinkler, S. Hahner, S. Wortmann et al., “Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 6, pp. 2057–2062, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Wortmann, M. Quinkler, C. Ritter et al., “Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma,” European Journal of Endocrinology, vol. 162, no. 2, pp. 349–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Fassnacht, M. C. Kreissl, D. Weismann, and B. Allolio, “New targets and therapeutic approaches for endocrine malignancies,” Pharmacology and Therapeutics, vol. 123, no. 1, pp. 117–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Berruti, A. Ferrero, P. Sperone et al., “Emerging drugs for adrenocortical carcinoma,” Expert Opinion on Emerging Drugs, vol. 13, no. 3, pp. 497–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. C. Laurell, D. Velázquez-Fernández, K. Lindsten et al., “Transcriptional profiling enables molecular classification of adrenocortical tumours,” European Journal of Endocrinology, vol. 161, no. 1, pp. 141–152, 2009. View at Google Scholar
  90. G. G. Fernandez-Ranvier, J. Weng, R. F. Yeh et al., “Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling,” Archives of Surgery, vol. 143, no. 9, pp. 841–846, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Haluska, F. Worden, D. Olmos et al., “Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 4, pp. 765–773, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. M. J. Mulvihill, A. Cooke, M. Rosenfeld-Franklin et al., “Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor,” Future Medicinal Chemistry, vol. 1, no. 6, pp. 1153–1171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Faivre, G. Kroemer, and E. Raymond, “Current development of mTOR inhibitors as anticancer agents,” Nature Reviews Drug Discovery, vol. 5, no. 8, pp. 671–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Doghman, A. El Wakil, B. Cardinaud et al., “Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by MicroRNA in childhood adrenocortical tumors,” Cancer Research, vol. 70, no. 11, pp. 4666–4675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Naing, R. Kurzrock, A. Burger et al., “Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer,” Clinical Cancer Research, vol. 17, no. 18, pp. 6052–6060, 2011. View at Google Scholar
  96. B. T. MacDonald, K. Tamai, and X. He, “Wnt/β-catenin signaling: components, mechanisms, and diseases,” Developmental Cell, vol. 17, no. 1, pp. 9–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Assie, T. J. Giordano, and J. Bertherat, “Gene expression profiling in adrenocortical neoplasia,” Molecular and Cellular Endocrinology, vol. 351, no. 1, pp. 111–117, 2012. View at Google Scholar
  98. B. Ragazzon, G. Assié, and J. Bertherat, “Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments,” Endocrine-Related Cancer, vol. 18, no. 2, pp. R15–R27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. F. Tissier, C. Cavard, L. Groussin et al., “Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors,” Cancer Research, vol. 65, no. 17, pp. 7622–7627, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Berthon, I. Sahut-Barnola, S. Lambert-Langlais et al., “Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development,” Human Molecular Genetics, vol. 19, no. 8, pp. 1561–1576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. B. P. Schimmer and P. C. White, “Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease,” Molecular Endocrinology, vol. 24, no. 7, pp. 1322–1337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. B. C. Figueiredo, L. R. Cavalli, M. A. Pianovski et al., “Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 2, pp. 615–619, 2005. View at Google Scholar
  103. M. A. D. Pianovski, L. R. Cavalli, B. C. Figueiredo et al., “SF-1 overexpression in childhood adrenocortical tumours,” European Journal of Cancer, vol. 42, no. 8, pp. 1040–1043, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Doghman, T. Karpova, G. A. Rodrigues et al., “Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer,” Molecular Endocrinology, vol. 21, no. 12, pp. 2968–2987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Doghman, J. Cazareth, D. Douguet, F. Madoux, P. Hodder, and E. Lalli, “Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 6, pp. 2178–2183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. M. J. Demeure, K. J. Bussey, and L. S. Kirschner, “Targeted therapies for adrenocortical carcinoma: IGF and beyond,” Horm Cancer, vol. 2, no. 6, pp. 385–392, 2011. View at Google Scholar
  107. C. L. Ronchi, S. Sbiera, L. Kraus et al., “Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy,” Endocrine-Related Cancer, vol. 16, no. 3, pp. 907–918, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Mistry, A. J. Stewart, W. Dangerfield et al., “In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576,” Cancer Research, vol. 61, no. 2, pp. 749–758, 2001. View at Google Scholar · View at Scopus
  109. J. Walker, C. Martin, and R. Callaghan, “Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy,” European Journal of Cancer, vol. 40, no. 4, pp. 594–605, 2004. View at Publisher · View at Google Scholar · View at Scopus